- Home
- ASIX vs AUTL Comparison
ASIX vs AUTL Comparison
Compare ASIX & AUTL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | ASIX | AUTL |
|---|---|---|
| Founded | 2016 | 2014 |
| Country | United States | United Kingdom |
| Employees | N/A | N/A |
| Industry | Major Chemicals | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Industrials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 506.7M | 433.8M |
| IPO Year | N/A | 2018 |
Fundamental Metrics
Financial Performance| Metric | ASIX | AUTL |
|---|---|---|
| Price | $18.64 | $1.41 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 2 | 3 |
| Target Price | ★ $25.50 | $8.33 |
| AVG Volume (30 Days) | 311.2K | ★ 1.4M |
| Earning Date | 02-20-2026 | 03-19-2026 |
| Dividend Yield | ★ 3.43% | N/A |
| EPS Growth | ★ 35.47 | N/A |
| EPS | ★ 1.92 | N/A |
| Revenue | ★ $1,491,348,000.00 | $51,128,000.00 |
| Revenue This Year | $1.02 | $672.42 |
| Revenue Next Year | $2.80 | $84.48 |
| P/E Ratio | $9.71 | ★ N/A |
| Revenue Growth | N/A | ★ 406.67 |
| 52 Week Low | $14.10 | $1.11 |
| 52 Week High | $31.03 | $2.70 |
Technical Indicators
Market Signals| Indicator | ASIX | AUTL |
|---|---|---|
| Relative Strength Index (RSI) | 57.27 | 47.94 |
| Support Level | $18.12 | $1.36 |
| Resistance Level | $19.50 | $1.48 |
| Average True Range (ATR) | 0.78 | 0.07 |
| MACD | 0.16 | 0.01 |
| Stochastic Oscillator | 70.13 | 76.47 |
Price Performance
Historical ComparisonAbout ASIX AdvanSix Inc.
AdvanSix Inc. is a diversified chemistry company playing a critical role in globally supply chains, innovating and delivering essential products for customers in a wide variety of end markets and applications that touch people's lives, such as building and construction, fertilizers, agrochemicals, plastics, solvents, packaging, paints, coatings, adhesives and electronics. The company key products includes: Nylon, Caprolactam, Plant Nutrients, and Chemical Intermediates The majority of sales is from Plant Nutrients products.
About AUTL Autolus Therapeutics plc
Autolus Therapeutics PLC is a biopharmaceutical company developing next-generation programmed T-cell therapies for the treatment of cancer. The company's clinical-stage pipeline comprises Obe-cel (obecabtagene autoleucel), AUTO1/22, AUTO3, AUTO5, AUTO6, AUTO7 & AUTO8.